BillionToOne is trading at $95.00, down 4.94%, amid broader market pressure.
- On October 7, 2026, equities fell, oil and Treasury yields rose, and investors were cautious ahead of Fed minutes; reports cited renewed Strait of Hormuz attacks.
- Biotech weakness added context: XBI was down 2.50%.
- BillionToOne announced a positive peer-reviewed study today, but reporting does not link it to the decline. Recent insider-sale disclosures have weighed on sentiment but are not a confirmed new catalyst.